EP
KPTI icon

Eversept Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Eversept Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133K Buy
+23,800
New +$181K 0.01% 120

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Eversept Partners's KPTI Position: Q1 2026 in Review

Eversept Partners opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 276,174 shares worth $1.54M. The stake represents 0.08% of the portfolio and ranks #95 among its holdings. This is a return to the name: Eversept Partners previously reported a position in KPTI as recently as Q2 2025.

Eversept Partners first reported a position in KPTI in Q1 2024 and has held it in 7 quarters since. The position peaked at $7.57M in Q1 2024. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Eversept Partners held 276,174 shares of Karyopharm Therapeutics worth $1.54M as of Q1 2026.
  • Karyopharm Therapeutics was a new Eversept Partners position in Q1 2026.
  • Karyopharm Therapeutics made up 0.08% of Eversept Partners's portfolio in Q1 2026, its #95 holding.
  • Eversept Partners first reported a position in Karyopharm Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Eversept Partners's Karyopharm Therapeutics position peaked at $7.57M in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.